4D Medicine – a UK company whose innovative biomaterial has potential to be used for a wide range of 3D printed implants and surgical devices - has raised £3.4m ($4.4m) in a Series A investment.  The funding round was led by Oshen Holdings and backed by DSW Ventures, SFC Capital, Boundary Capital and private investors including several leading scientists and surgeons. It will enable the company to complete pre-clinical testing of its first product range and seek FDA clearance for entry into the US market.

Global pharmaceutical company Eli Lilly and Company has acquired Aparito, the Wrexham-based med-tech business set up by Dr Elin Haf Davies and part-funded by the Development Bank of Wales who now exit with an initial return of 2.9x on their £1.2 million equity investment.

The Development Bank of Wales has led a £1.75 million round in a biotech company currently working on demonstrating a new type of drug to treat cardiovascular disease. Argonaute RNA Ltd is a biotech business developing gene-targeting drugs to treat a rare form of heart disease called severe familial cholesterolaemia (or FH).  It has long-term plans to use similar drugs to tackle common conditions.

Amber Therapeutics (Tx), a start-up involving the University of Oxford, has just completed a $100 million Series A funding round from healthcare and technology investors in the US and UK to develop treatment for mixed urinary incontinence.

Animal Health Angels has invested in MI:RNA, the veterinary diagnostics company using cutting-edge technology and science to transform animal health diagnosis, as part of a $4 million in Series A funding round. 

Aiming to change the future of animal health treatments through improved, earlier diagnostics, the capital will be used to continue global growth plans and revolutionise animal health testing, improving diagnosis and wellness among the pet, agriculture and equine sectors. MI:RNA’s vision is to change the approach to disease diagnosis to improve animals’ outcomes. The merits of MI:RNA technology are scientifically reviewed and proven, winning numerous grants and awards.

USA: Central Texas Angel Network (CTAN) has announced the closing of its first investment of the year, with an investment over $500,000 in Endomedix, Inc., a medical technology company leveraging cutting-edge technology to deliver unparalleled performance and safety in controlling surgical bleeding. Notably, CTAN's investment in Endomedix includes a substantial contribution from the CTAN Sidecar Fund.

Edinburgh-based 1nhaler, which is backed by Archangels, has appointed two experts in inhalation and respiratory medicines to the Board as it looks to accelerate the development and market-readiness of its novel single use inhaler device.

London based startup Cryogenx, whose portable body cooling device offers a rapid response for heat-related illness, has secured a £150,000 investment from British Design Fund, as part of a wider £800,000 raise that included existing shareholders, angel investors and a US-based fund.

Nanomaterial producer iGii has raised £8.8 million of new funding to accelerate growth. The Stirling-based company, formerly known as Integrated Graphene, will use the funds to accelerate customer projects, increase its manufacturing capacity, and deepen its research and development to explore further applications of its patented Gii^TM material. iGii plans to expand its facilities and continue creating highly skilled local jobs.

Floreon Technology, a cutting-edge bioplastics firm which was spun out of a successful partnership with the University of Sheffield is set to receive a £250,000 investment from CPI Enterprises.

OGI Bio, a leading Scottish biotechnology company, has secured follow-on funding of £650,000 in a deal led by TRICAPITAL Angels and supported by Scottish Enterprise, Merleview, Apollo, and Old College Capital to accelerate the company's growth and expansion in the UK, EU, and US biotechnology sectors.

Evoralis Ltd is one of the first company to benefit from the programme and its investment portfolio will be managed by CPI Enterprises, the investment arm of CPI.